AUTOLUS THERAPEUTICS PLC (AUTL)
US05280R1005 - ADR
AUTL Makes Notable Cross Below Critical Moving Average
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO...
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024...
RSI Alert: Autolus Therapeutics (AUTL) Now Oversold
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Announces Changes to its Board of Directors...
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates...
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site...
Autolus Therapeutics announces publication in Blood Cancer Journal
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024...
Autolus Therapeutics announces publication in Nature Communications
BioNTech to invest $200M in Autolus as part of a CAR-T deal (NASDAQ:AUTL)
BioNTech (BNTX) agrees to invest $200M in Autolus Therapeutics (BNTX) for co-development and commercialization of CAR-T cell therapies. Read more here.
Autolus Announces Pricing of Underwritten Offering
Autolus Announces Pricing of Underwritten Offering
Autolus Announces Pricing of Underwritten Offering...
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs...
Autolus Therapeutics announces publication in ACS Chemical Biology
Autolus Therapeutics announces publication in ACS Chemical Biology
Autolus Therapeutics announces publication in ACS Chemical Biology ...
Autolus stock gains on FDA review for obe-cel (NASDAQ:AUTL)
The FDA accepts Autolus Therapeutics (AUTL) marketing application for CAR-T cell therapy, obe-cel, targeting adult B-cell acute lymphoblastic leukemia. Read more here.
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL...
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Autolus Therapeutics appoints Elisabeth Leiderman to board (NASDAQ:AUTL)
Autolus Therapeutics makes changes to its board of directors with the appointment of Elisabeth Leiderman and the resignation of Kapil Dhingra.
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Announces Changes to its Board of Directors
Autolus Therapeutics Announces Changes to its Board of Directors...
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023...